Neratinib
Sign in to save this workspacePrimary targets: ERBB2_HER2 · FDA status: FDA Approved
Selectivity scorecard
KISS
93.18
Gini
0.597
CATDS
0.010
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Neratinib. Strongest target: EGFR at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 100.0% | 0.0% |
| 2 | ERBB4_HER4 | 99.7% | 0.3% |
| 3 | ERBB2_HER2 | 99.7% | 0.3% |
| 4 | GLK_MAP4K3 | 99.7% | 0.3% |
| 5 | LCK | 99.3% | 0.7% |
| 6 | STK25_YSK1 | 99.2% | 0.8% |
| 7 | KHS_MAP4K5 | 99.0% | 1.0% |
| 8 | TNIK | 98.9% | 1.1% |
| 9 | MST4 | 98.7% | 1.3% |
| 10 | MST3_STK24 | 98.3% | 1.7% |
| 11 | MINK_MINK1 | 98.3% | 1.7% |
| 12 | BLK | 98.2% | 1.8% |
| 13 | HGK_MAP4K4 | 98.1% | 1.9% |
| 14 | C_MER | 97.8% | 2.2% |
| 15 | HPK1_MAP4K1 | 97.7% | 2.4% |
| 16 | SIK1 | 96.4% | 3.6% |
| 17 | AXL | 96.3% | 3.7% |
| 18 | ACK1 | 95.2% | 4.8% |
| 19 | JAK3 | 95.2% | 4.8% |
| 20 | YES_YES1 | 94.3% | 5.7% |
Selectivity landscape
Where Neratinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Neratinib.
Annotations
Sign in to read and post annotations.
Loading…